Merck Animal Health Completes Acquisition of Poultry Sense Limited

Proprietary Technology Enhances Health and Environmental Monitoring Solutions for Poultry Producers

Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its acquisition of PrognostiX Poultry Limited d/b/a Poultry Sense Ltd. from its founding shareholders. Poultry Sense Ltd. is an innovator in health and environmental monitoring solutions for the poultry industry. In March 2019, Merck Animal Health invested in Poultry Sense Ltd., to support their development. Specific terms of the agreement were not disclosed.

Poultry Sense Ltd., a privately held company located in Exeter, U.K., provides enhanced technology for poultry farmers to continuously track and analyze overall health performance for the life of the flock; it provides users the capability to measure, compare and record key health and environmental indicators captured by battery-powered, wireless sensors in the poultry barn, as well as to identify patterns and trends to predict health and well-being and, ultimately, prevent disease and improve performance.

This innovative technology is an important tool used to assess an animal's health and well-being, which contributes to enhanced productivity and efficacy measures on the farm and, ultimately, to better food safety and security. The sensors allow farmers to monitor and assess vital parameters by measuring weight, water usage, humidity, light, temperature and carbon dioxide. Farmers can therefore gain insight into the housing environment, as well as bird health and performance.

This proprietary technology can detect health conditions earlier in poultry that can lead to illness, thus reducing the potential for disease outbreak. This notification is done via software reports in an easy-to-read dashboard in real-time on any mobile device, desktop, tablet or secure website, which also connects to the cloud.

"We are pleased to take this step forward with the acquisition of Poultry Sense Ltd., as we continue to broaden our portfolio with complementary products and technologies to advance animal well-being and outcomes for our customers," said Rick DeLuca, president, Merck Animal Health. "We now will be able to provide enhanced health and environmental monitoring technology to the poultry industry, which adds to our technological expertise within our livestock monitoring business with beef and dairy cattle as well as aquaculture, strengthening our leadership in shaping the future of animal health."

"Our goal is to improve the detection of animal illness and enable more preventative solutions, including vaccination, to maintain the health of livestock. We are at the technological forefront of shaping the future of animal health through our commitment to leveraging our scientific and technical capabilities and expertise through comprehensive solutions to manage the health, well-being and performance of animals."

The Poultry Sense Ltd. product portfolio joins Merck Animal Health Intelligence, a newly formed specialized operating unit which takes its name from the company's strategic vision for animal health intelligence and data expertise. Merck Animal Health Intelligence is a complementary business that specializes in identification, traceability, monitoring solutions and services to help improve animal management and health outcomes.

"The addition of specialized, digital technology within our portfolio of medicines, vaccines and services, provides holistic solutions to help advance animal health and complements our existing identification and monitoring technology that delivers real-time, actionable data and insights to help, improve or enhance animal management and health outcomes," said DeLuca.

"I am delighted that Merck Animal Health has chosen to acquire this tremendous technology," said Alan Beynon, CEO of PrognostiX. "They have the expertise and geographic range to expand the footprint of this product and reach more customers."

In April 2019, Merck Animal Health announced the completion of its acquisition of market leading brands Allflex Livestock Intelligence, Sure Petcare and Biomark as leaders in emerging digital technology with animal identification, animal monitoring and smart data management for Livestock and Companion Animals. In December 2019, the company acquired Vaki, a leader in fish farming and wild fish conservation monitoring equipment and real-time video monitoring technology to advance fish health and welfare. In June 2020, the company acquired Quantified Ag ® , an innovator in data and analytics that monitors cattle body temperature and movement in order to detect illness early. In August 2020, the company acquired IdentiGEN, a leader in DNA-based animal traceability solutions for Livestock and Aquaculture.

About Merck Animal Health

For 130 years, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck. Through its commitment to The Science of Healthier Animals® , Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn , Facebook , and Twitter at @MerckAH.

Poultry Sense Limited

Poultry Sense combines a wealth of expertise and evidence with the knowledge of specialist vets, engineers and data analysts to bring together real-time data across both environmental and health parameters to help facilitate improvements in bird performance, economics and welfare.

The wireless system feeds accurate, live data into a bespoke analytics platform that uses artificial intelligence to produce insight assisting in better informed on-farm and supply chain decision making. For more information contact: info@poultrysendltd.com .

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2019 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( www.sec.gov ).

Merck
Media Contacts:

Jeanette Lewis
+ 1 (973) 294-0318
Jeanette.Lewis@merck.com

Patrick Ryan
+1 (973) 275-7075
Patrick.ryan4@merck.com

Merck
Investor Contact:

Michael DeCarbo
+ 1 (908) 740-1807
Michael.DeCarbo@merck.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)

Jamieson Wellness Inc. Announces Date of First Quarter 2024 Financial Results and Conference Call

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the Company will release its first quarter 2024 financial results after the market close on Thursday, May 9, 2024. The Company will host a conference call for investors at 5:00 p.m. Eastern Time to discuss the first quarter 2024 results.

The call can be accessed live over the telephone by dialing 1-800-717-1738 from Canada and the U.S. or 1-646-307-1865 from international locations. A replay will be available shortly after the call and can be accessed by dialing 1-844-512-2921 from Canada and the U.S. or 1-412-317-6671 from international locations. The passcode for the replay is 1179130 and it will be available until Thursday, May 23, 2024.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Pill package with up arrow.

Top 3 Canadian Pharma Stocks of 2024

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.

Three months into 2024, market watchers are keeping a close eye on pharma companies vying for the next major innovation.

Here the Investing News Network lists the top Canadian pharma stocks trading on the Toronto Stock Exchange (TSX) and the TSX Venture Exchange (TSXV). Companies considered had market caps above C$100 million and were arranged based on year-on-year performance. All data was compiled on April 16, 2024, using TradingView’s stock screener.

Keep reading...Show less

New Novartis Fabhalta® data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy

  • APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN 1

  • IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide 2 ; complement activation is a key driver of glomerular inflammation in IgAN 3,4

  • There is a need for effective, targeted therapies for IgAN 2,5 ; up to 30% of patients with persistent proteinuria (≥1 g/day) may progress to kidney failure within 10 years, requiring maintenance dialysis and/or kidney transplantation 6

  • Novartis continues to advance broad renal portfolio in late-stage development, exploring the potential to slow disease progression and extend dialysis-free life

Novartis today presented results from a pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta ® (iptacopan), an investigational Factor B inhibitor of the alternative complement pathway, in patients with IgA nephropathy (IgAN) 1 . In the analysis, patients treated with Fabhalta achieved a 38.3% (p

Proteinuria reduction is an increasingly recognized surrogate marker correlating with progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated approvals 7 . The study also showed that Fabhalta was well tolerated with a favorable safety profile consistent with previously reported data 1,8 . Results were presented today during a late-breaking clinical trials session at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina 1 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer

Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas' preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties –

– Novartis to be responsible for worldwide clinical development and commercialization of ARV-766 –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

New Novartis data show early addition of twice-yearly* Leqvio® following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

  • V- INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively) 1
  • A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm while maintaining adherence to statin treatment 1
  • Results from usual care arm reinforce the urgent need for more aggressive LDL-C lowering in ASCVD patients, 92% of whom did not reach their LDL-C goal with statins alone 1
  • The Leqvio safety profile was consistent with the Phase III clinical studies and long-term open-label extension trials for up to 6 years of treatment 1-4

Novartis today announced new data demonstrating the early addition of twice-yearly* Leqvio ® (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), including those with a history of an ASCVD-related event, who could not reach their goal on statin therapy alone 1 . The late-breaking data were presented at the 2024 American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in the Journal of the American College of Cardiology .

"V-INITIATE evaluated a solution to the important challenge seen in clinical practice of too many patients with ASCVD not achieving guideline-recommended LDL-C goal on statins alone and effective non-statin therapies being markedly underutilized," said Michael Koren , M.D., Medical Director and CEO of Jacksonville Center for Clinical Research, and the primary investigator of the study. "Given the urgent need to more aggressively manage LDL-C, the results from V-INITIATE show that when added earlier in the treatment continuum, the structured use of effective non-statin therapies like Leqvio can significantly reduce LDL-C for ASCVD patients who are struggling to reach or maintain their LDL-C goal."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×